ライフサイエンスコーパス: aAPC

1 aAPC are based on artificial membrane bilayers containin

2 aAPC-generated cells also produced more of each cytokine

3 aAPC-induced cultures showed robust antigen-specific CTL

4 aAPCs modified to coexpress OX40L or 4-1BBL expanded UCB

5 s mostly expand naive cells, anti-CD3/4-1BBL aAPCs preferentially expand memory cells, resulting in s

6 g HLA-A2-Fc fusion proteins linked to 4-1BBL aAPCs, 3-log expansion of Ag-specific CD8+ CTL was induc

7 ass I/II and CD1 expression, we generated an aAPC expressing CD1c as the sole Ag-presenting molecule.

8 scribes the translation of the SB system and aAPC for use in clinical trials and highlights how a nim

9 by stimulation with peptide-loaded moDCs and aAPCs, T cell function, assessed by expression of IL-2,

10 of human polyclonal T cells (artificial APC (aAPC)).

11 study, using a novel CD1c(+) artificial APC (aAPC)-based system, we isolated human CD1c-restricted au

12 Artificial APCs (aAPCs) consisting of magnetic beads coated with Abs to H

13 Artificial APCs (aAPCs) genetically modified to express selective costimu

14 (moDCs) or HLA-A2-Ig-based artificial APCs (aAPCs).

15 Cell-based aAPCs can effectively expand cytolytic CD8+ cells, but o

16 uman cytolytic CD8+ T cells using cell-based aAPCs providing costimulation via 4-1BB vs CD28.

17 These studies show the value of HLA-Ig-based aAPCs for reproducible expansion of disease-specific CTL

18 HLA-Ig-based aAPCs were used to induce and expand CTLs specific for c

19 Compared with beads, aAPCs had similar expansion properties while significant

20 When stimulated with this CD1c(+) aAPC presenting endogenous lipids, a subpopulation of pr

21 Whereas anti-CD3/anti-CD28 aAPCs mostly expand naive cells, anti-CD3/4-1BBL aAPCs p

22 sion did not occur using HLA-A2-Fc/anti-CD28 aAPCs.

23 Using an artificial antigen-presenting cell (aAPC) that can process both the N- and C-termini of endo

24 ed with artificial antigen-presenting cells (aAPC) can selectively propagate and thus retrieve CAR(+)

25 NHL on artificial antigen presenting cells (aAPC) in the presence of human interleukin (IL)-2 and IL

26 CD19(+) artificial antigen-presenting cells (aAPC).

27 Artificial antigen-presenting cells (aAPCs) are an emerging technology to induce therapeutic

28 veloped artificial antigen-presenting cells (aAPCs) expressing ligands for the T-cell receptor (TCR)

29 l-based artificial antigen-presenting cells (aAPCs) preloaded with anti-CD3/28 mAbs to achieve higher

30 issue, artificial antigen-presenting cells (aAPCs) were made by coupling a soluble human leukocyte a

31 In conclusion, aAPCs expand T(CM) that have extensive replicative capac

32 Engineered aAPC may have immediate application for basic and clinic

33 UCB Tregs expanded with 4-1BBL expressing aAPCs had decreased levels of proapoptotic bim.

34 culture conditions of expanding T cells from aAPCs to moDCs, and moDCs to aAPCs, reversed the phenoty

35 Further stimulation with peptide-loaded aAPC increased purity to >99% Ag-specific T cells.

36 Peptide-loaded aAPC were not sufficient to induce resting CD4 T(CM) to

37 Tregs expanded with nonmodified or modified aAPCs versus beads resulted in higher survival associate

38 tly greater extent than bead- or nonmodified aAPC cultures, reaching mean expansion levels exceeding

39 mutein of IL-21 bound to the cell surface of aAPC that replaced the need for soluble IL-21.

40 Among the variety of aAPCs that have been studied, acellular beads expressing

41 To fully replace natural APCs, an optimized aAPC must present antigen (signal 1), provide costimulat

42 ved when we used either soluble tetramers or aAPC in which MHC-peptide complexes were uniformly distr

43 e release of IL-2 from biodegradable polymer aAPCs (now termed paAPCs) can significantly alter the ba

44 TNF-alpha, MIP1beta, and CD107a, showed that aAPC-generated CD8(+) T cells were multifunctional, wher

45 These aAPCs reproducibly activate and rapidly expand polyclona

46 These results suggest that this aAPC-based approach enables the biochemical identificati

47 ng T cells from aAPCs to moDCs, and moDCs to aAPCs, reversed the phenotypes.

48 novel approach for UCB Treg expansion using aAPCs, including those coexpressing OX40L or 4-1BBL.